Shares of Tango Therapeutics Inc. (TNGX) touched an all-time high of $18.97 yesterday as the company progresses through 2026 with a focused commitment to execution, building on the substantial advancements across its development portfolio in 2025.
This clinical-stage biotechnology company is developing the next generation of precision cancer medicines. Its lead drug candidate is Vopimetostat, also known as TNG462, a potent and selective PRMT5 (Protein Arginine Methyltransferase 5) inhibitor. PRMT5 is an enzyme that is often overactive in certain cancers, helping tumor cells grow and survive.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com